JP2019536778A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536778A5
JP2019536778A5 JP2019526008A JP2019526008A JP2019536778A5 JP 2019536778 A5 JP2019536778 A5 JP 2019536778A5 JP 2019526008 A JP2019526008 A JP 2019526008A JP 2019526008 A JP2019526008 A JP 2019526008A JP 2019536778 A5 JP2019536778 A5 JP 2019536778A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019526008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536778A (ja
JP7383285B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061854 external-priority patent/WO2018093936A1/en
Publication of JP2019536778A publication Critical patent/JP2019536778A/ja
Publication of JP2019536778A5 publication Critical patent/JP2019536778A5/ja
Application granted granted Critical
Publication of JP7383285B2 publication Critical patent/JP7383285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019526008A 2016-11-15 2017-11-15 肺高血圧症の治療及び予防における2-ヒドロキシベンジルアミンの使用 Active JP7383285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15
US62/422,486 2016-11-15
PCT/US2017/061854 WO2018093936A1 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Publications (3)

Publication Number Publication Date
JP2019536778A JP2019536778A (ja) 2019-12-19
JP2019536778A5 true JP2019536778A5 (enExample) 2020-12-24
JP7383285B2 JP7383285B2 (ja) 2023-11-20

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019526008A Active JP7383285B2 (ja) 2016-11-15 2017-11-15 肺高血圧症の治療及び予防における2-ヒドロキシベンジルアミンの使用

Country Status (9)

Country Link
US (2) US20190314302A1 (enExample)
EP (2) EP4385576A3 (enExample)
JP (1) JP7383285B2 (enExample)
CN (1) CN110177463B (enExample)
AU (1) AU2017362328B2 (enExample)
ES (1) ES2981715T3 (enExample)
HU (1) HUE067036T2 (enExample)
PL (1) PL3541185T3 (enExample)
WO (1) WO2018093936A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
CN113677202B (zh) * 2019-01-25 2024-03-08 范德比尔特大学 靶向线粒体的异缩酮/isolevuglandin清除剂
MX2022009256A (es) * 2020-01-27 2022-10-07 Univ Vanderbilt Depuradores de isocetal/isolevuglandina dirigidos a la mitocondria y usos de los mismos.
AU2021360501A1 (en) * 2020-10-13 2023-06-22 Vanderbilt University Method of preventing kidney injury disruption of intestinal lymphatics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167411A1 (en) 2003-03-27 2007-07-19 Medicure International Inc. Compositions for treating angina
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
JP5132109B2 (ja) 2006-09-01 2013-01-30 花王株式会社 一剤式染毛剤組成物
EP3111933B1 (en) * 2006-11-13 2019-09-04 PCB Associates, Inc. Prophylaxis or treatment of glomerulosclerosis
US8314015B2 (en) 2010-07-14 2012-11-20 Sharp Laboratories Of America, Inc. Silicon surface modification for the electrochemical synthesis of silicon particles in suspension
CA2844150C (en) 2011-07-12 2019-09-03 Vanderbilt University Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
US20150031068A1 (en) * 2012-03-19 2015-01-29 Lycera Corporation Methods and compositions for detecting immune system activation
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Similar Documents

Publication Publication Date Title
JP2014500861A5 (enExample)
JP2019536778A5 (enExample)
JP2016534063A5 (enExample)
JP2013523733A5 (enExample)
JP2013032389A5 (enExample)
JP2014515013A5 (enExample)
JP2017523225A5 (enExample)
JP2017537940A5 (enExample)
JP2017514910A5 (enExample)
JP2017528503A5 (enExample)
JP2018135343A5 (enExample)
JP2012184234A5 (enExample)
JP2012532883A5 (enExample)
JP2017141277A5 (enExample)
JP2018537535A5 (enExample)
JP2016522254A5 (enExample)
JP2017511377A5 (enExample)
JP2015508068A5 (enExample)
JP2018530608A5 (enExample)
JP2017508817A5 (enExample)
JP2016508145A5 (enExample)
JP2023022236A5 (enExample)
JP2015504917A5 (enExample)
JPWO2023054292A5 (enExample)
JP2012511558A5 (enExample)